Romine

Background 19 Plaintiff Jacqueline R. Romine (“Plaintiff”) initiated this action with the filing of a 20 complaint on November 25, 2024, alleging claims for damages against Defendants Pfizer, Inc., 21 Pharacia & Upjohn Co. LLC, Pharmacia LLC, and Viatris Inc. (“Defendants”) arising from 22 Defendants’ wrongful conduct in connection with the development, design, testing, 23 manufacturing, labeling, packaging, promoting, advertising, marketing, distribution, and selling 24 of medroxyprogesterone acetate (“MPA”), also known as depot medroxyprogesterone acetate 25 (“DMPA”), and as a prescription drug under the trade name Depo-Provera® (“Depo-Provera”). 26 (Doc. 1 ¶ 1). Defendants’ respective responses to the complaint are due to be filed by late- 27 December 2024 or early-January 2025. (Docs. 9-13). 28 Stipulated Request to Stay Pending before the Court is the parties’ stipulated request for order staying the action pending a determination of a petition before the Judicial Panel on Multidistrict Litigation (“JPML”). (Doc. 14). The parties represent that they are aware of at least 33 other actions pending in United States District…